The interaction between human serum albumin and antidiabetic agent - exenatide: determination of the mechanism binding and effect on the protein conformation by fluorescence and circular dichroism techniques - Part I.
J Biomol Struct Dyn · 2020
Last updated 2026-05-28This study examined how the diabetes drug exenatide interacts with human blood proteins under lab conditions. The binding strength between exenatide and the protein was measured at around 10 M, and this interaction weakened when common metals like calcium, zinc, or chromium were present. Exenatide slightly increased the protein's structure near a specific part called tryptophan-214 but did not change the overall protein shape. Metal ions also affected the protein's structure in a similar way.
AI summary of the abstract below.
| Journal | J Biomol Struct Dyn, 2020 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 0.89 |
| NIH percentile | 46 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
The interactions between transport proteins and drugs are very important from the pharmacological point of view. In this study, using fluorescence and circular dichroism (CD) techniques, we investigated the interaction between human serum albumin (HSA) and incretin antidiabetic drug - exenatide. Moreover, the effect of common metal ions (Ca, Zn, Cr) on the exenatide-HSA binding - was also described. Based on the experimental data under pseudophysiological conditions, the calculated binding constant values are on the order of 10 M, and the constants are lower in the presence of metal ions. We observed the increase of the hydrophobicity near the tryptophan-214 residue in subdomain IIA, but almost no change in the hydrophobicity surrounding tyrosine residues. A similar effect on the tryptophan microenvironment is influenced by metal ions. The calculated thermodynamic parameters indicated that the characteristic electrostatic and hydrophobic interactions play an important role in the albumin-exenatide complexes. The CD studies showed that exenatide does not change the secondary structure of the protein but used metal ions have some impact on albumin α-helical content.Communicated by Ramaswamy H. Sarma.
Verbatim abstract via PubMed 31232198 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.